Pancreatic cancer
… Rachna T Shroff, MD Rachna T Shroff … Correspondence to: Dr Rachna T Shroff, Division
of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, …
of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, …
[HTML][HTML] Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it …
The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation,
Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD …
Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD …
Mechanistic insights into vascular calcification in CKD
Cardiovascular disease begins early in the course of renal decline and is a life-limiting problem
in patients with CKD. The increased burden of cardiovascular disease is due, at least in …
in patients with CKD. The increased burden of cardiovascular disease is due, at least in …
Machine learning-aided engineering of hydrolases for PET depolymerization
Plastic waste poses an ecological challenge 1, 2, 3 and enzymatic degradation offers one,
potentially green and scalable, route for polyesters waste recycling 4. Poly (ethylene …
potentially green and scalable, route for polyesters waste recycling 4. Poly (ethylene …
[PDF][PDF] Integrated genomic characterization of pancreatic ductal adenocarcinoma
…, Y Stephen, Z Howard, M Judy, A Breggia, RT Shroff… - Cancer cell, 2017 - cell.com
We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic
ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low …
ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low …
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Background Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of
patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor …
patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor …
Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline
…, A Leaf, WM Remak, RT Shroff… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical
decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS ASCO …
decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS ASCO …
The measure and mismeasure of fairness
… To generalize our setting in Section 3, we consider arbitrary utility functions of the form u : X
→ R. As before, for a function u and decision policy d, we write u(d) = E[d(X) · u(X)] to denote …
→ R. As before, for a function u and decision policy d, we write u(d) = E[d(X) · u(X)] to denote …
Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial
Importance Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20%
of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free …
of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free …
[HTML][HTML] Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
… Alpini G, Prall R, LaRusso NFThe pathobiology of biliary epithelia, in Arias IM, Boyer JL, Chisari
… Turner N, Grose R: Fibroblast growth factor signalling: From development to cancer. Nat …
… Turner N, Grose R: Fibroblast growth factor signalling: From development to cancer. Nat …